 |
2 Diseases |  |
27 Trials |
|
27 Trials |  |
1089 News |  |
| «12345678910111213...1516» |
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal: Heart failure therapy: the fifth card. (Pubmed Central) - Apr 24, 2023
In the VICTORIA study, the molecule vericiguat, a soluble guanylate cyclase activator, was shown to reduce the composite outcome of death from cardiovascular causes and first hospitalization for HF in a high-risk population. An additional randomized clinical trial (VICTOR) is ongoing to evaluate the efficacy and safety of vericiguat in a population with HF on optimized therapy and with no recent episodes of stabilization.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
🔹 Einziger pharmazeutischer Partner bisher @Bayer (Vericiguat > verbessert Durchblutung) 🔹 Betont den Standortvorteil Deutschlands durch langjährige #MECFS-Forschung u. a. an der Charité (Twitter) - Apr 19, 2023
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Vericiguat for the treatment of heart failure with reduced ejection fraction. (Pubmed Central) - Apr 19, 2023
Almost 90% of the patients with HFrEF were adherent to the 10 mg dose of vericiguat in the VICTORIA trial with a favorable tolerability and safety profile. Considering the high residual risk that persists in HFrEF, vericiguat has a role to improve outcomes among patients with worsening HFrEF.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Biomarker, Journal: Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure with Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. (Pubmed Central) - Apr 18, 2023
hs-cTnT, growth differentiation factor-15, and interleukin-6 levels were associated with risk of the primary outcome in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction). Uniquely, lower hs-cTnT was associated with a lower rate of cardiovascular death but not HF hospitalization after treatment with vericiguat.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. (Pubmed Central) - Apr 14, 2023
The addition of vericiguat to the treatment regimen of Chinese patients with HF with reduced ejection fraction following an HF exacerbation resulted in an incremental cost-effectiveness ratio of $89,429 USD/QALY compared to standard treatment. This incremental cost-effectiveness ratio exceeds the willingness-to-pay threshold and thus, vericiguat was deemed not cost effective in the Chinese population.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
New P4 trial, Surgery: SOLSTICE: SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery (clinicaltrials.gov) - Apr 14, 2023
P4, N=170, Not yet recruiting, Sponsor: Vanderbilt University Medical Center
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
New P2 trial: A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction (clinicaltrials.gov) - Apr 10, 2023
P2, N=50, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | New P4 trial: ANF-HF: Strategy, Efficacy and Safety of Medication Usage in Heart Failure Patients Who Were Intolerable to GDMT (clinicaltrials.gov) - Apr 5, 2023
P4, N=60, Not yet recruiting, Sponsor: Chongqing Medical University
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Review, Journal: Management of Heart Failure with Reduced Ejection Fraction. (Pubmed Central) - Mar 28, 2023
Specific groups of patients with HFrEF may also be candidates for various device therapies such as implanted cardioverter defibrillators, cardiac resynchronization therapy and transcatheter mitral valve repair. This review provides a comprehensive overview of drug and device management approaches for patients with HFrEF, recommendations for initiation and titrations of therapies, and challenges associated with guideline directed medical therapy in the management of patients with HFrEF.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Review, Journal: Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review. (Pubmed Central) - Mar 28, 2023
The safety of the vericiguat, according to our review, is not up to the standards, especially with a higher dosage of vericiguat. Despite all of this, vericiguat can be a breakthrough in the treatment of heart failure as it has great potential to improve the disease severity.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy (Pubmed Central) - Mar 28, 2023
This ANMCO position paper summarizes key aspects of vericiguat mechanism of action and provides a review of available clinical evidence. Furthermore, this document reports use indications based on international guideline recommendations and local regulatory authority approval at the time of writing.
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Review: In this extremely vital and need of the time drug profile published in Expert Review of Cardiovascular Therapy, we discuss the role of Vericiguat in patients with HFrEF, despite guideline-directed medical therapy. W/ Drs @ShahzebKhanMD, @JavedButler1 @robmentz @FudimMarat (Twitter) - Mar 25, 2023
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Review, Journal: Practical Patient Care Considerations with Use of Vericiguat After Worsening Heart Failure Events. (Pubmed Central) - Mar 20, 2023
This review provides an overview of vericiguat therapy and proposes an evidence-based and practical guidance strategy towards implementing its use in various clinical settings. This review additionally summarizes patient counseling points for its initiation and maintenance.
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
“There is no such thing as Stable #HF”- @BiykemB as she discusses #4pillars #GDMT Followed by @jteerlinkmd discussing #Vericiguat #Omecativ beyond #4pillars High yield session on medical therapy in #HF #THT2023 @JavedButler1 @dranulala @EricAdler17 (Twitter) - Mar 20, 2023
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
@jteerlinkmd sports the @JCardFail swag representing @HFSA and helps us tease out: who benefits and perhaps doesn’t benefit from vericiguat? Very challenging to find a place for use of this therapy actually. (Twitter) - Mar 20, 2023
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Probalo! Es más eficaz que el vericiguat! (Twitter) - Mar 15, 2023
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Retrospective data, Review, Journal: Efficacy and safety of vericiguat in heart failure: a meta-analysis. (Pubmed Central) - Mar 15, 2023
This review additionally summarizes patient counseling points for its initiation and maintenance. This meta-analysis indicated that vericiguat was not an effective drug for HF; however, more clinical trials are required to verify its efficacy.
- || Verquvo (vericiguat) / Bayer, Merck (MSD), moxifloxacin intravenous / Generic mfg.
Clinical, Journal: Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. (Pubmed Central) - Mar 14, 2023
P1
This meta-analysis indicated that vericiguat was not an effective drug for HF; however, more clinical trials are required to verify its efficacy. As part of an integrative risk assessment, this study demonstrated no clinically relevant corrected QT prolongation with vericiguat 10 mg once daily at steady state.
- || Verquvo (vericiguat) / Bayer, Merck (MSD), sildenafil / Generic mfg.
PK/PD data, Journal: Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. (Pubmed Central) - Mar 13, 2023
5.4 mmHg) compared with administration of sildenafil alone. There was no effect of sildenafil on vericiguat pharmacokinetics, and an increase in sildenafil exposure with vericiguat co-administration was not clinically relevant.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
Impact of Inclusion of Vericiguat in the Burden of Disease of Heart Failure with Reduced Ejection Fraction (HFREF) and Worsening HF Event in Colombia () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1358;
Vericiguat has a positive impact on clinical benefit for HFrEF and WHF patients. In patient subgroups where hospitalization is high (3 or more re-hospitalizations) health care system savings are generated
- Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Simple Approach for Developing Parametric Survival Based Cost-Effectiveness Analysis (CEA): Case Study of Heart Failure with Reduced Ejection Fraction (HFREF) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_844;
Simulated IPD based simpler CEA showed high match to IPD based models. This simple approach could be useful to develop early CEAs.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: The optimization of guideline-directed medical therapy during hospitalization among patients with heart failure with reduced ejection fraction in daily clinical practice. (Pubmed Central) - Mar 2, 2023
This simple approach could be useful to develop early CEAs. High rates of application of disease-modifying drugs are achievable among hospitalized HFrEF patients in severe clinical condition, thus awareness of the need for the initiation of the former must be raised.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
Initial experience of early post-discharge assessment in patients with heart failure and reduced ejection fraction (ePosters Station 10) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_1555;
As a secondary endpoint, the aim is to evaluate which patients are candidates for Vericiguat therapy (recent episode of heart failure decompensation requiring hospitalization and intravenous treatment)...Early evaluation after discharge in patients with heart failure with reduced ejection fraction allows, on the one hand, adequate optimization of medical treatment, with the consequent repercussions on hospital readmissions and echocardiographic parameters, and, on the other hand, improved therapeutic adherence with a reduction in possible adverse effects. The main limitation of our study lies in the small sample size.
- BioVAT / Repairon
Safety and efficacy of induced pluripotent stem cell-derived engineered human myocardium as biological ventricular assist tissue in term. heart failure (BioVAT-HF):trial design and experience at UKSH (Moderated ePosters 3) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_1313;
Median age (Q1, Q3) was 63 (60, 66) years, all patients were male (100%). Baseline parameters were: NYHA class 3 (3, 3), INTERMACS level 6 (5.5, 7), left ventricle (LV) ejection fraction 20 (16, 20)%, LV enddiastolic-diameter 61 (54, 77) mm, TAPSE 22 (14, 23) mm, NT-proBNP 941 (643, 8618) ng/l, 6-minute walking distance 331 (302, 350) m, glomerular filtration rate 52 (35, 71) ml/min.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
Heart failure with worsening event and outcomes in real world setting (ePosters Station 10) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_1029;
However, approximately half of these patients were non-eligible for vericiguat. The benefit of vericiguat in this population should be further evaluated.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
Real-world analysis of heart failure medication before and after hospitalization for heart failure. Data from two large cohorts in the US and Germany. (Moderated ePosters 3) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_691;
A new medication prescribed after the HFH was observed in 33.6% (25,274) and in 36.1% (16,947) of patients in the US and Germany, respectively. The greatest portion of new users were observed in MRAs and loop diuretics.
- |||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Enrollment open: VALOR: Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (clinicaltrials.gov) - Feb 27, 2023
P2/3, N=342, Recruiting, Sponsor: Merck Sharp & Dohme LLC
The greatest portion of new users were observed in MRAs and loop diuretics. Not yet recruiting --> Recruiting
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: #clinicalquestion Have you ever Rx Vericiguat? Typically don't think of this in the armamentarium for HFrEF maybe for the pt with hospitalization, low BP/inability to tolerate further GDMT? @gcfmd @MKIttlesonMD @HFSA @jacc https://t.co/4xpMmvdrYf (Twitter) - Feb 23, 2023
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Excellent discussions at the #WorseningHeartFailure (WHF) dialogue in Mumbai‼️ #Vericiguat, the novel stimulator of soluble guanylate cyclase, is indicated in #HFrEF after a WHF event @JavedButler1 @JustinEzekowitz @ShelleyZieroth @GiuseppeGalati_ (Twitter) - Feb 17, 2023
- |||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
New trial, Real-world evidence, Real-world: An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China (clinicaltrials.gov) - Feb 15, 2023
P=N/A, N=2400, Not yet recruiting, Sponsor: Bayer
- |||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Just to be clear, I do think vericiguat has a place in HFrEF management. But my priority is always on getting patients on optimal doses of foundational therapy first with proven benefits to morbidity/mortality. Then I start adding the other novel therapies (Twitter) - Feb 11, 2023
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Of course! No question, and thank you for highlighting Dr. @gcfmd The question above, at least as I see it, is how hard clinicians should also pushing on things like vericiguat in addition to the core pillars of GDMT (Twitter) - Feb 11, 2023
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Where does vericiguat fit for patients with HFrEF? @gcfmd @SJGreene_md @JavedButler1 @_adevore @kofi_larry https://t.co/d4LCAFhotB (Twitter) - Feb 9, 2023
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Applicability of Vericiguat to Patients Hospitalized for Heart (Pubmed Central) - Feb 8, 2023
Not yet recruiting --> Recruiting Data from a large, contemporary U.S. registry of patients actively hospitalized for HF with EF
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Vericiguat in HFrEF: Insights From the GWTG-HF Registry. (Pubmed Central) - Feb 8, 2023
Data from a large, contemporary U.S. registry of patients actively hospitalized for HF with EF No abstract available
- Verquvo (vericiguat) / Bayer, Merck (MSD)
The new comer: vericiguat (Room 4; Online) - Feb 8, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_266;
- Verquvo (vericiguat) / Bayer, Merck (MSD)
Vericiguat (Agora 1) - Feb 8, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_57;
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Preclinical, Journal: Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy. (Pubmed Central) - Feb 7, 2023
These results unravel sGC stimulation can improve skeletal muscle atrophy and increase the exercise capacity of mice in response to DOX treatment by enhancing protein synthesis and inhibiting protein degradation. Stimulation of sGC may be a potential treatment of DOX-induced skeletal muscle dysfunction.
- |||||||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
New P2/3 trial: VALOR: Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (clinicaltrials.gov) - Feb 6, 2023
P2/3, N=342, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
Journal: Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization. (Pubmed Central) - Feb 3, 2023
Stimulation of sGC may be a potential treatment of DOX-induced skeletal muscle dysfunction. The majority of patients admitted with AHF are eligible for foundational quadruple therapy and additional novel medications across a spectrum of HF phenotypes.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
New P2 trial: Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction (clinicaltrials.gov) - Feb 3, 2023
P2, N=45, Not yet recruiting, Sponsor: Johns Hopkins University
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Biomarker: In @JCardFail, @ChrisDefilippi, @coconnormd et al. VICTORIA Study Group. evaluated biomarkers of cardiac injury, inflammation, and renal function for associations with outcomes and vericiguat treatment effect https://t.co/rqhevOqVbL (Twitter) - Feb 2, 2023
- | Journal: Advances in contemporary medical management to treat patients with heart failure. (Pubmed Central) - Feb 1, 2023
Vericiguat benefits high risk patients with worsening HF clinical profile. Most patients hospitalized with HF can be up-titrated to high doses of GDMT within weeks and this approach reduces the likelihood of adverse HF outcomes.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
New P4 trial: Impact of Vericiguat on Hemodynamics of Heart Failure (clinicaltrials.gov) - Jan 30, 2023
P4, N=30, Not yet recruiting, Sponsor: University of Colorado, Denver
- |||| Verquvo (vericiguat) / Bayer, Merck (MSD)
New P2a trial: Study to Investigate Improvement in Physical Function in SF-36 with Vericiguat Compared with Placebo in Participants with Post-COVID-19 Syndrome (clinicaltrials.gov) - Jan 26, 2023
P2a, N=104, Not yet recruiting, Sponsor: Charite University, Berlin, Germany
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Review: 🔥 Beautiful recent review on known mechanisms of #HF #therapies 🍀 Complementary actions 🔬 Need for further research about #SGLT2i #Vericiguat #Omecamtiv #ARNI @JavedButler1 @CVR_TomaszGuzik @IzzaShahid_ @gcfmd @JJheart_doc @gbiondizoccai @DrMarthaGulati @KTamirisaMD @iamritu (Twitter) - Jan 24, 2023
- || Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, Merck (MSD)
Review, Journal: Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. (Pubmed Central) - Jan 22, 2023
Based on the CHEST-1 and PATENT-1 trials, riociguat was introduced into clinical practice for treating chronic thromboembolic pulmonary hypertension (CTEPH). In January 2021, the FDA approved the use of another drug, vericiguat, for the treatment of heart failure.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Review, Journal: Emerging concepts in heart failure management and treatment: focus on vericiguat. (Pubmed Central) - Jan 21, 2023
In addition, relevant data on other previous studies are also provided in both HF with reduced LVEF (SOCRATES-Reduced) and HF with preserved LVEF (SOCRATES-Preserved and VITALITY-Preserved). This article is part of the Emerging concepts in heart failure management and treatment Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment.
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Enrollment open, Real-world evidence, Real-world: A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction) (clinicaltrials.gov) - Jan 18, 2023
P4, N=200, Recruiting, Sponsor: Bayer
This article is part of the Emerging concepts in heart failure management and treatment Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment. Not yet recruiting --> Recruiting
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Review, Journal: Vericiguat: A New Hope for Heart Failure Patients. (Pubmed Central) - Jan 10, 2023
Vericiguat was approved by the FDA in January of 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic heart failure and ejection fraction less than 45%. In this review, we describe the chemical and mechanistic aspects, pharmacokinetics, adverse effects, and contraindications of vericiguat so as to facilitate its optimal therapeutic use.